Announcing my newest blog!

I invite you to visit my new blog, Cancer Confidant, where I share more valuable information for people dealing with cancer on topics such as diet, exercise, fatigue, etc.  Go to cancerconfidant.org.  For personalized guidance, contact me at cancer.confidant@gmail.com.

Ibrutinib for Mantle Cell Lymphoma

Ibrutinib (Imbruvica) has been FDA approved for the treatment of mantle cell lymphoma who have received at least one prior therapy.

New treatment for CLL

Gazyva (obinutuzumab) now approved for use in combination with chlorambucil for previously untreated CLL patients (chronic lymphocytic leukemia).

Perjeta approved for use before surgery

Perjeta approved by the FDA today for patients with locally advanced, HER2+, inflammatory or early-stage breast cancer who are at high risk for recurrence or metastases used in combination with Herceptin and other chemotherapy before surgery.  After surgery, patients should continue on Herceptin to complete one year of treatment.

New combo in met pancreatic cancer

Abraxane in combination with gemcitabine is now approved as first-line treatment in metastatic pancreatic cancer.

New Drug Approved for Lung Cancer

Gilotrif (afatinib) is now FDA approved for first-line treatment of metastatic non-small cell lung cancer with specific EGFR mutations.

Two new drugs for advanced melanoma!

Tafinlar and Mekinist are now approved for advanced malignant melanoma.  Tafinlar is approved for patients with the BRAF V600E gene mutation.  Mekinist is approved for patients with either the BRAF V600E or V600K gene mutations.